<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>5
<FILENAME>sinovacexh99_3.txt
<DESCRIPTION>SINOVAC BIOTECH 6K, PRESS RELEASE, 11.26.04
<TEXT>


EXHIBIT 99.3
------------



                              SINOVAC BIOTECH LTD.
                              --------------------
           APPROVED FOR LISTING ON THE AMERICAN STOCK EXCHANGE (AMEX)
           ----------------------------------------------------------


BEIJING,  November 26, 2004 - Sinovac Biotech Ltd.  ("Sinovac")  ("the Company")
(NASD OTC-BB:  SNVBF)  announces  that the American  Stock Exchange has approved
Sinovac's  application  for the  listing of the  Company's  common  stock.  This
approval is contingent  upon the Company being in compliance with all applicable
listing  standards  on the date it begins  trading on the  Exchange,  and may be
rescinded if the Company is not in compliance with such standards. Shares of the
Company's  common  stock are  expected to begin  trading on the  American  Stock
Exchange under the symbol "SVA" within 10 to 15 business days.

Sinovac  president,  Dr. Wei Dong Yin commented,  "Progressing onto the American
Stock Exchange represents the achievement of another significant  milestone that
we had set for 2004. This accomplishment is an important step in the building of
a strong  foundation  upon which we can grow our vaccine  business both in China
and  internationally.  In the near  future,  we are  also  expecting  the  final
approval of our  hepatitis  A&B vaccine for sale in China and the  completion of
our SARS vaccine Phase I clinical trial."

Dr.  Yin  added,  "Sinovac  is  pleased  to be  joining  the  growing  number of
biotechnology  companies  listed on the American  Stock  Exchange.  This listing
further  validates  Sinovac's   fundamental   business   reputation,   corporate
governance,  and future  potential.  With the listing on the AMEX,  we expect to
benefit from greater  accessibility  to institutional  investment,  better share
price stability,  greater share liquidity,  and an overall increase in Sinovac's
visibility in the investment community."

AMEX  approval  of Sinovac is one more step in  achieving  Sinovac's  vision for
becoming   one   of   China's   leading   biotechnology   companies:   providing
state-of-the-art vaccines that combat some of the world's most virulent viruses.

For further details on the Company's approval for listing on AMEX please contact
Sinovac  Investor  Relations  toll-free at (888) 888 8312 or 1 604 684 5990 from
outside North America.


About the American Stock Exchange
---------------------------------

The American  Stock  Exchange(R)  (Amex(R)) is the only  primary  exchange  that
offers  trading  across a full range of equities,  options and  exchange  traded
funds (ETFs),  including structured products and HOLDRS(sm).  In addition to its
role as a  national  equities  market,  the  Amex  is the  pioneer  of the  ETF,
responsible for bringing the first domestic  product to market in 1993.  Leading
the industry in ETF listings,  the Amex lists 143 ETFs.  The Amex is also one of
the largest  options  exchanges in the U.S.,  trading options on broad-based and
sector  indexes as well as domestic and foreign  stocks.  For more  information,
please visit http://www.amex.com.
             -------------------


About Sinovac Biotech Ltd.
--------------------------

Sinovac    Biotech   Ltd.    specializes    in   the   research,    development,
commercialization,  and sales of human vaccines for infectious illnesses such as
hepatitis A and hepatitis B, influenza, "SARS", and avian flu. Sinovac is one of
the leading  emerging  biotechnology  companies in China.  Working  closely with
Chinese public health officials,  Sinovac focuses on manufacturing and marketing
human-use  vaccines and related products,  and currently markets its vaccine for
hepatitis A. Sinovac is the first and currently the only company in the world to
have commenced clinical trials for a vaccine to prevent SARS.



<PAGE>






Management invites  shareholders and interested parties to email media articles,
or indeed  any  information  that  relates  to  Sinovac,  its  vaccines  and the
respective viruses that each one treats, to info@sinovac.com. Articles that have
                                            ----------------
already been published will be added to a media library on the Sinovac  web-site
which is currently being  re-designed,  and new articles that are received on an
ongoing basis will be posted regularly.

For further  information  please refer to the Company's  filings with the SEC on
EDGAR or refer to Sinovac's website at www.sinovac.com.
                                       ---------------

If you would like to receive  regular  updates on Sinovac please send your email
request to info@sinovac.com.
           ----------------


Contact:   Investor   Relations   at  (888)  888  8312  or  (604)   684-5990  or
info@sinovac.com
----------------




THIS NEWS RELEASE MAY INCLUDE  FORWARD-LOOKING  STATEMENTS WITHIN THE MEANING OF
SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION
21E OF THE UNITED STATES  SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED,  WITH
RESPECT  TO  ACHIEVING  CORPORATE  OBJECTIVES,   DEVELOPING  ADDITIONAL  PROJECT
INTERESTS,   SINOVAC'S   ANALYSIS  OF   OPPORTUNITIES  IN  THE  ACQUISITION  AND
DEVELOPMENT  OF VARIOUS  PROJECT  INTERESTS  AND CERTAIN  OTHER  MATTERS.  THESE
STATEMENTS  ARE MADE UNDER THE "SAFE  HARBOR"  PROVISIONS  OF THE UNITED  STATES
PRIVATE  SECURITIES  LITIGATION  REFORM  ACT  OF  1995  AND  INVOLVE  RISKS  AND
UNCERTAINTIES  WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER  MATERIALLY FROM THOSE
IN THE  FORWARD-LOOKING  STATEMENTS  CONTAINED  HEREIN.  THE  AMEX  APPROVAL  IS
CONTINGENT  UPON  SINOVAC  BEING  IN  COMPLIANCE  WITH  ALL  APPLICABLE  LISTING
STANDARDS ON THE DATE IT BEGINS TRADING ON THE AMERICAN STOCK EXCHANGE,  AND MAY
BE RESCINDED IF THE COMPANY IS NOT IN COMPLIANCE WITH SUCH STANDARDS.




</TEXT>
</DOCUMENT>
